Tempus ECG-AF vs Irregular Rhythm Notification Feature (IRNF)
AI Verdict
Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if your healthcare facility requires an FDA-cleared, AI-based algorithm to proactively identify patients aged 65 or older at increased risk of developing new-onset atrial fibrillation within the next 12 months. This tool is ideal for integrating into existing cardiology workflows to enhance clinical risk stratification and support earlier intervention based on 12-lead ECG analysis within a controlled medical environment.
View Tempus ECG-AF →Choose Irregular Rhythm Notification Feature (IRNF) if…
Choose the Irregular Rhythm Notification Feature if you are a consumer seeking a convenient, over-the-counter wearable solution for continuous, passive screening of irregular heart rhythms suggestive of AFib in your daily life. This feature empowers individuals to receive proactive notifications on their Apple Watch, facilitating timely discussions with their physicians about potential cardiac concerns.
View Irregular Rhythm Notification Feature (IRNF) →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Tempus ECG-AF | Irregular Rhythm Notification Feature (IRNF) |
|---|---|---|
| Pricing | Contact vendor | Included with apple watch purchase |
| Deployment | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. | Device-based (Apple Watch), integrated with the iPhone Health app. |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Yes AI-estimated | Yes AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Irregular Rhythm Notification Feature (IRNF)Tool B (Apple's IRNF) is designed for direct consumer use via the Apple Watch and iPhone Health app, offering an intuitive and accessible experience with an onboarding process and educational materials. Tool A (Tempus ECG-AF) is a software solution integrated into healthcare facility systems, requiring clinical workflows and professional operation, making it less directly 'usable' for the general public.
Clinical Value
Tempus ECG-AFTool A (Tempus ECG-AF) provides a predictive risk assessment for developing AF within 12 months, utilizing a 12-lead ECG in a clinical setting, which offers a deeper, proactive clinical insight for a specific patient population. Tool B (IRNF) is a screening tool on a wearable device that detects irregular rhythms suggestive of AFib, empowering users to initiate discussions with physicians, but it does not offer the same level of predictive clinical insight from a gold-standard diagnostic.
Pricing & Value
Tempus ECG-AFTool A (Tempus ECG-AF) has a clear, established CMS reimbursement pathway (CPT 0764T and CPT 0765T with a Medicare rate of $128.90), providing a quantifiable value proposition within the healthcare billing structure. Tool B (IRNF) is included with the purchase of an Apple Watch, bundling its value with a consumer device rather than having a direct, reimbursable healthcare service cost.
Enterprise Readiness
Tempus ECG-AFTool A (Tempus ECG-AF) is explicitly designed as a software solution for integration into healthcare facility systems, offers a Business Associate Agreement (BAA), and is HIPAA compliant, making it robustly enterprise-ready. Tool B (IRNF) lacks a BAA for the feature itself, which presents a significant barrier for covered entities in healthcare seeking to integrate it into their enterprise systems.
Innovation
TieBoth tools demonstrate significant innovation in different domains. Tool A (Tempus ECG-AF) innovates by applying AI for predictive risk assessment of future AF from a single 12-lead ECG, advancing proactive clinical diagnostics. Tool B (IRNF) innovates by democratizing continuous, passive AFib screening through a widely accessible consumer wearable, significantly expanding population-level health monitoring.
Support & Docs
Irregular Rhythm Notification Feature (IRNF)Tool B (IRNF) benefits from Apple's extensive consumer-facing support infrastructure, offering readily accessible educational materials, FAQs, and troubleshooting guides for a broad user base. While Tool A (Tempus ECG-AF) provides professional support channels for healthcare facilities, the public accessibility and breadth of documentation for general users are likely less comprehensive than Apple's consumer-focused approach.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Tempus ECG-AF | Irregular Rhythm Notification Feature (IRNF) |
|---|---|---|
| Name | Tempus ECG-AF | Irregular Rhythm Notification Feature (IRNF) |
| Company | Tempus AI, Inc. | Apple |
| Description | FDA-cleared AI-based algorithm that analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months, supporting earlier identification and follow-up. | FDA-cleared Irregular Rhythm Notification Feature (IRNF) for Apple Watch screens for irregular heart rhythms suggestive of AFib, empowering users with notifications to facilitate discussions with their physicians. |
| Target Patient Population | Patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery. | Users 22 years old and over, not previously diagnosed with AF. |
| Data Source for Analysis | 12-lead ECG recordings. | Pulse rate data from Apple Watch photoplethysmography (PPG) sensor. |
Videos
Demos, reviews, and walkthroughs featuring Tempus ECG-AF and Irregular Rhythm Notification Feature (IRNF).